Activating Mutations in the Epidermal Growth Factor Receptor Underlying Responsiveness of Non–Small-Cell Lung Cancer to Gefitinib-Reference-Cited by-同舟云学术

Activating Mutations in the Epidermal Growth Factor Receptor Underlying Responsiveness of Non–Small-Cell Lung Cancer to Gefitinib

Published:2004-05-20 Issue:21 Volume:350 Page:2129-2139
ISSN:0028-4793
Container-title:New England Journal of Medicine
language:en
Short-container-title:N Engl J Med

Author:

Lynch Thomas J.,Bell Daphne W.,Sordella Raffaella,Gurubhagavatula Sarada,Okimoto Ross A.,Brannigan Brian W.,Harris Patricia L.,Haserlat Sara M.,Supko Jeffrey G.,Haluska Frank G.,Louis David N.,Christiani David C.,Settleman Jeff,Haber Daniel A.

Publisher

Massachusetts Medical Society

Subject

General Medicine

Link

http://www.nejm.org/doi/pdf/10.1056/NEJMoa040938

Cited by 9992 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Novel EGFR inhibitors against resistant L858R/T790M/C797S mutant for intervention of non-small cell lung cancer;European Journal of Medicinal Chemistry;2024-11

2. Targeting EGFR by Newer 1-(3,5-Bis((E)-4‑hydroxy-3-methoxystyryl)-1H-pyrazol-1-yl)-2-((substituted phenyl)amino)ethan-1-one Analogues for the Treatment of Cancer: Synthesis, In-vitro and In-silico Studies;Journal of Molecular Structure;2024-11

3. Optimal systemic treatment and real-world clinical application of ctDNA in patients with metastatic HER2-mutant lung cancer;European Journal of Cancer;2024-10

4. Unlocking the future of cancer diagnosis – promises and challenges of ctDNA-based liquid biopsies in non-small cell lung cancer;Translational Research;2024-10

5. Analysis of EGFR binding hotspots for design of new EGFR inhibitory biologics;Protein Science;2024-09-14